Expression of hepatocyte growth factor in breast cancer and its effect on prognosis and sensitivity to chemotherapy

Yang,Hua; Zhang,Chongjian; Cui,Shude

doi:10.3892/mmr.2014.2808

Expression of hepatocyte growth factor in breast cancer and its effect on prognosis and sensitivity to chemotherapy

Authors:
- Hua Yang
- Chongjian Zhang
- Shude Cui
View Affiliations

Affiliations: Department of Breast Surgery, Henan Tumor Hospital, Zhengzhou, Henan 450003, P.R. China
Published online on: October 29, 2014 https://doi.org/10.3892/mmr.2014.2808
Pages: 1037-1042

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine the expression of hepatocyte growth factor (HGF) in breast cancer and its effect on prognosis and sensitivity to chemotherapy. Immunohistochemistry was conducted to determine the expression of HGF in 125 breast cancer patients. The correlation between the expression level of HGF and the effect of preoperative chemotherapy or 5‑year survival rate was then investigated. The human breast cancer cell line, MCF‑7, was transfected with a HGF‑small interfering (si)RNA interference sequence. Reverse transcription quantitative polymerase chain reaction and western blot analysis were used to confirm the interference efficiency of HGF‑siRNA. An MTT assay was used to detect the proliferative activity of MCF‑7 cells following silencing of HGF and during co‑culture with epirubicin (EPI) at different concentrations. HGF was highly expressed in breast cancer patients and was not associated with patient age, location, size or hormone receptor status of the tumor (P>0.05), however, HGF expression was associated with tumor‑node‑metastasis (TNM) clinical stage, histological grade, lymph node metastasis and prognosis (P<0.05). The efficiency of chemotherapy in HGF negative patients (90%) was significantly higher (P<0.05) compared with HGF positive patients (68.75%). Following successful downregulation of HGF by HGF‑siRNA, the tolerance to EPI decreased in MCF‑7 cells. In conclusion, HGF was highly expressed in breast cancer cells and was closely associated with lymph node metastasis, prognosis and sensitivity to chemotherapy. Therefore, HGF may be a potential indicator of the prognosis and effectiveness of chemotherapy for breast cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Wang L, Wang C, Su B, et al: Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo. Biochem Cell Biol. 91:526–531. 2013. View Article : Google Scholar : PubMed/NCBI
3	Singh-Kaw P, Zarnegar R and Siegfried JM: Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial cells. Am J Physiol. 268:L1012–L1020. 1995.PubMed/NCBI
4	Parr C, Watkins G, Mansel RE and Jiang WC: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res. 10:202–211. 2004. View Article : Google Scholar : PubMed/NCBI
5	Jiang W, Hiscox S, Matsumoto K and Nakamura T: Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol. 29:209–248. 1999. View Article : Google Scholar : PubMed/NCBI
6	El-Attar HA and Sheta MI: Hepatocyte growth factor profile with breast cancer. Indian J Pathol Microbiol. 54:509–513. 2011. View Article : Google Scholar : PubMed/NCBI
7	Gallego MI, Bierie B and Hennighausen L: Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene. 22:8498–8508. 2003. View Article : Google Scholar : PubMed/NCBI
8	Huang S, Ouyang N, Lin L, et al: HGF-induced PKCζ activation increases functional CXCR4 expression in human breast cancer cells. PLoS One. 7:e291242012. View Article : Google Scholar
9	Siegfried JM, Weissfeld LA, Luketich JD, Weyant RL, Gubish CT and Landreneau RJ: The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg. 66:1915–1918. 1998. View Article : Google Scholar
10	Locatelli A, Lofgren KA, Daniel AR, Castro NE and Lange CA: Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm Cancer. 3:14–25. 2012. View Article : Google Scholar
11	Woodbury RL, Varnum SM and Zangar RC: Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. J Proteome Res. 1:233–237. 2002. View Article : Google Scholar
12	Hirose Y, Kojima M, Sagoh M, Murakami H, Yoshida K, Shimazaki K and Kawase T: Immunohistochemical examination of c-Met protein expression in astrocytic tumors. Acta Neuropathol. 95:345–351. 1998. View Article : Google Scholar : PubMed/NCBI
13	Takeuchi H, Bilchik A, Saha S, et al: c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res. 9:1480–1488. 2003.PubMed/NCBI
14	Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T and Shin S: Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 54:1630–1633. 1994.PubMed/NCBI
15	Sheen-Chen SM, Liu YW, Eng HL and Chou FF: Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev. 14:715–717. 2005. View Article : Google Scholar : PubMed/NCBI
16	Eichbaum MH, de Rossi TM, Kaul S, Bruckner T, Schneeweiss A and Sohn C: Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumour Biol. 28:36–44. 2007. View Article : Google Scholar
17	Lengyel E, Prechtel D, Resau JH, et al: C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 113:678–682. 2005. View Article : Google Scholar
18	Minuti G, Cappuzzo F, Duchnowska R, et al: Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer. 107:793–799. 2012. View Article : Google Scholar : PubMed/NCBI
19	Parr C and Jiang WG: Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer. 119:1176–1183. 2006. View Article : Google Scholar : PubMed/NCBI
20	Knuefermann C, Lu Y, Liu B, et al: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003. View Article : Google Scholar : PubMed/NCBI